BPS 2022 Proceedings
Meienhofer Keynote Address
Stephen Kent
Professor
University of Chicago
Chemical Protein Synthesis – my Journey from SPPS to Chemical Ligation
Peptide Showcase
Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.
Morten Lundh
Project Leader
Gubra
The streaMLine platform for accelerated clinical candidate identification
Massina Abderrahmane
Data Scientist
Iktos Inc
Representing, predicting, and generating simple and complex peptides
Dani Stoltzfus
Senior Director R & D Chemistry
NeuBase Therapeutics
Developing PNAs into Biotherapeutics
Ved Srivastava
Vice President, chemistry
Aktis Oncology
Realizing the curative power of alpha radiopharmaceuticals for mainstream cancer care
John McGee
Vice President and Scientific Co-Founder
FOG Pharmaceuticals Inc
Platforms for the Rapid Discovery of Helical Peptide Therapeutics
Sally Wang Liang
SVP of BD
PepLib
Beyond Binders: High-Throughput Peptide Screening for Functionally Active Hits
Lucas Siow
CEO and Co-Founder
ProteinQure Inc
Structure-driven exploration of non-canonical amino acid space for optimized peptide ligands
Patrick Salveson
VP Research and Discovery
Vilya
Computational macrocycle design with drug-like properties for targeted therapeutics
Dominik Sarma
Managing Director
Belyntic GmbH
Faster time-to-market with Peptide Easy Clean (PEC)
Spotlight on Discovery
Presentations of applied research from the academic labs.
Helena Safavi-Hemami
Associate Professor
University of Copenhagen, Denmark
Hormone-Like Peptides from Venomous Animals as Optimized Drug Leads for Disease
Christina Schroeder
Senior Fellow
Genentech
Recifin A, a Novel and Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I with a Unique Disulfide-bond Topology
Ashlee Rowe
Assistant Professor
University of Oklahoma
Structure and Mechanism of a Novel Scorpion Peptide that Inhibits Nav1.8, a Voltage-Gated Sodium Channel Regulator of Pain Signal Transmission
Peptides in the Clinic
Updates on clinical development of peptide therapeutics.
Bernhard Fischer
CEO
APEPTICO
Clinical development of the solnatide peptide for the treatment of ARDS and COVID-19 during the corona pandemics. Identification of the 3D conformational ensemble of solnatide by crystallography and NMR
Johannes Koebberling
Senior Science Fellow
Bayer AG
Discovery and Early Development of Adrenomedullin Pegol (BAY 1097761) for the Treatment of ARDS – First Disclosure
Dieter Willbold
Director
Forschungszentrum Jülich
The All-D-Peptide PRI-002: Preclinical PoC and Clinical Phase Ib Data from Alzheimer’s Disease Patients
David Huang
CMO
Peptilogics
Engineered Peptide PLG0206 Overcomes Activity, Safety, and Pharmacokinetic Limitations of a Challenging Drug Class
Thomas Kruse
Senior Principal Scientist
Novo Nordisk
Preclinical and Clinical Development of Long-acting Amylin Agonists
Geoff Harris
Founder Ocelot Bio
Ocelot Bio
Designing a Mixed Agonist-Antagonist Peptide: A Case Study of OCE-205 in Advanced Liver Disease
Drug Delivery
Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies
John Lewis
Professor
University of Alberta
Fusogenix Proteolipid Vehicles (PLVs) utilize fusion-associated transmembrane proteins to deliver DNA or RNA by direct fusion
Kevin McDonnell
VP Chemistry
Bicycle Therapeutics
Bicycles® are versatile vehicles for precision guided drug delivery
Ratmir Derda
Chief Operating Officer
48Hour Discovery
Novel, Peptide-Based Radiopharmaceuticals for the Treatment of Various Solid Tumors
Manuel Sanchez-Felix
Senior Fellow
Novartis
Patient-centric design for systemic peptide delivery: Trends in routes of administration and advancement in drug delivery technologies
Patrick Dougherty
Senior Scientist
Entrada Therapeutics
Development of Endosomal Escape Vehicles to Enhance the Intracellular Delivery of Oligonucleotides
Chemistry of Complex Peptides
Michal Avital-Shmilovici
Senior Scientist and Research Lead
SRI International
Mega-Throughput Screening of Large OBOC Non-Natural Peptide Libraries Using Fiber Optic Array Scanning Technology
Patrick Knerr
Senior Director & Site Head
Novo Nordisk Research Center Indianapolis
Discovery and Optimization of Long-Acting, Unimolecular Peptide Triple Agonists of the GLP-1, GIP, and Glucagon Receptors
Michael Stowell
Professor
University of Colorado – Boulder
Structural Complexities of Insulin Receptor Signaling
Les Miranda
Executive Director, R&D & CMC Operations
Amgen
GIPR antagonist antibodies conjugated to GLP-1 peptide are multispecific molecules that decrease weight in obese mice & monkeys
Hiroaki Suga
Professor
The University of Tokyo
Display and RaPID Selection of Pseudo-Natural Peptides and Products
Workshops and Panels
Pharma Circle Panel
Greg Adams
Associate Director Discovery Chemistry • Drug Design
Former Merck & Co. / Currently at Exscientia
Start-Up Workshop
CEO Roundtable Discussion
Sponsored Presentations
Product and capability presentation from our sponsors
William Fang
VP, Head of New Modality Oligo/Peptide Business
STA Pharmaceutical
CMC Strategies and New Technology Applications for the Development of Peptide Drugs
Matteo Villain
Vice President CMC Development
Bachem
A New Linker for Peptide Bioconjugation – The Thiazine
Dale Thomas
Co-founder
Mytide Therapeutics
Cutting-Edge Chemistry: Harnessing AI-Based Robotics for Industry Changing, Fully Automated Peptide Production
Colton Quick
Product Specialist
Gyros Protein Technologies
From Small to Large Scale: Optimizing and Upscaling the Synthesis of Melanotan II (MT-II) – Melanocortin Receptor Agonist, on PurePep® Chorus and PurePep® Sonata+
Jonathan Loughrey
Physical Sciences Manager
Almac Group
The Advantages of Peptide Crystallization for Purification, Stability, and IP
Jonathan Collins
Vice President Business Development
CEM Corporation
Wash Free, One-Pot Fmoc Solid Phase Peptide Synthesis